Synthetic method of SDNX-5613 and intermediate compound of SDNX-5613

By using sulfuric acid/hydrogen peroxide system and water as solvents, the synthesis route of SNDX-5613 was optimized, and the problems of unstable reactions and high cost in the existing technology were solved, and an efficient and safe synthesis process was achieved, which improved product yield and simplification. Process steps.

CN118994033AActive Publication Date: 2024-11-22HITGEN INC
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202310554819.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-17
Publication Date
2024-11-22
Estimated Expiration
2043-05-17

AI Technical Summary

Technical Problem

In the existing synthetic methods of SNDX-5613, the use of m-chlorperoxybenzoic acid and urea peroxide leads to increased acidity, resulting in unstable reactions, numerous by-products, high equipment requirements, and the use of oxychloride is dangerous. and high cost, the final step yield is low, the synthesis route is linear synthesis, and the time cost is high.

Method used

Use sulfuric acid/hydroperoxide system to replace m-chlorperoxybenzoic acid, use water as solvent, and directly condense intermediate compounds 2-2 and 3-3 by optimizing reaction conditions and condensation steps, avoid phosphorus oxychloride and organic solvents, and simplify synthesis. route.

Benefits of technology

Reduced reagent costs, avoided by-product generation and environmental pollution, simplified post-treatment steps, improved reaction safety and yield, shortened synthesis time and cost, and optimized synthesis route.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention discloses a synthesis method of a menin inhibitor SNDX-5613 (Revumenib) and an intermediate compound of the menin inhibitor SNDX-5613 (Revumenib). The synthesis method is high in yield and low in cost, phosphorus oxychloride is not used, and the safety is improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of chemical synthesis, and specifically relates to a synthesis method of a menin inhibitor SNDX-5613 (Revumenib) and an intermediate compound thereof. Background Art

[0002] Mixed lineage leukemia (MLL) proteins are histone methyltransferases that are mutated in clinically and biologically distinct subtypes of acute leukemia. Spontaneous translocation of the MLL1 gene leads to the production of MLL-r fusion protein, which interacts with the menin protein, leading to the abnormal activation of a series of gene clusters and the occurrence of leukemia. Menin-MLL interaction inhibitors are epigenetic inhibitors that can block the interaction between menin and MLL fusion protein (MLL-r) in leukemia cells. SNDX-5613 is an inhibitor of the interaction between menin and MLL fusion protein developed by Syndax. It entered Phase I / II clinical studies on August 22, 2019 and is the first Menin-MLL inhibitor to enter clinical studies.

[0003] The chemical name of SNDX-5613 is N-ethyl-2-((4-(7-(((1r,4r)-4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide, the English name is N-ethyl-2-((4-(7-(((1r,4r)-4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide, the drug name is Revumenib, and its chemical structure is as follows:

[0004]

[0005] Existing reports (such as WO2017214367A1 and CN109743875A) all use meta-chloroperbenzoic acid or urea peroxide to oxidize the pyrimidine ring, then use phosphorus oxychloride to chlorinate, then use diazaspiro [3.5] ring nucleophilic substitution, and finally replace with sulfonamide fragment (S1) to construct the corresponding structure. The first step requires the use of meta-chloroperbenzoic acid or urea peroxide. The use of meta-chloroperbenzoic acid will cause the acidity of the system to increase, resulting in diaryl ether bond breaking, making the reaction yield of this step low and unstable. The acidic system also has high requirements for the reaction and treatment equipment. In addition, the reaction will also produce a large amount of meta-chlorobenzoic acid by-products. Urea peroxide is a controlled reagent and is currently difficult to obtain on the market. The second step requires phosphorus oxychloride. Similarly, excessive acidity may cause diaryl ether bond breaking, which has high requirements for the reaction equipment, and the post-processing is cumbersome and quite dangerous. The yield of the last step is too low, mainly because the diaryl ether fragment is easy to break under this condition. In addition, the entire synthesis route is a linear synthesis, which has high time cost.

[0006] In order to overcome the shortcomings of the prior art, the present invention provides a method for synthesizing SNDX-5613 and an intermediate compound thereof with mild reaction conditions, simple operation and a more reasonable route. Summary of the invention

[0007] The present invention provides an intermediate compound for synthesizing menin inhibitor SNDX-5613, which has formula 2-2 and / or

[0008] The structure shown in formula 3-3:

[0009]

[0010] Preferably, the synthesis method of the intermediate compound 2-2 comprises step (3):

[0011] (3) Dissolve compound 1-1 in a solvent, add an oxidant to oxidize under the action of an acid, and react at 50-70° C. for 16-24 hours to obtain an intermediate compound 2-2;

[0012] The reaction route is as follows:

[0013]

[0014] Preferably, the synthesis method of the intermediate compound 3-3 comprises step (1) and step (2):

[0015] (1) Dissolve compound S1 and a catalyst in a solvent, stir for 10 to 30 minutes, then add a base and compound 3-1, heat to 70 to 80°C under nitrogen protection, and react for 12 to 24 hours to obtain intermediate 3-2;

[0016] (2) Dissolving the intermediate 3-2 in a solvent, adding an acid to remove the protecting group, and obtaining the intermediate compound 3-3;

[0017] The reaction route is as follows:

[0018]

[0019] Preferably, a method for synthesizing the menin inhibitor SNDX-5613 comprises the following steps:

[0020] (1) Dissolve compound S1 and a catalyst in a solvent, stir for 10 to 30 minutes, then add a base and compound 3-1, heat to 70 to 80°C under nitrogen protection, and react for 12 to 24 hours to obtain intermediate 3-2;

[0021] (2) Dissolving the intermediate 3-2 in a solvent, adding an acid to remove the protecting group, and obtaining the intermediate compound 3-3;

[0022] (3) Dissolve compound 1-1 in a solvent, add an oxidant to oxidize under the action of an acid, and react at 50-70° C. for 16-24 hours to obtain an intermediate compound 2-2;

[0023] (4) The intermediate compound 2-2 is dissolved in a solvent, and reacted with the intermediate compound 3-3 at 0-30° C. for 12-24 h in the presence of a condensing agent and a base to obtain SNDX-5613.

[0024] The reaction route is as follows:

[0025]

[0026] Preferably, in step (1), the molar ratio of compound S1 to the catalyst, compound 3-1 and base is 1:(0.8-1):(0.5-1):(3-5), and the amount of solvent used is 4-15 mL of solvent per 1 g of compound S1.

[0027] Preferably, the catalyst in step (1) is any one or more of potassium iodide and sodium iodide.

[0028] Preferably, the base in step (1) is any one or more of potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide and lithium hydroxide.

[0029] Preferably, the solvent in step (1) is any one or more of NMP (N-methylpyrrolidone), DMSO (dimethyl sulfoxide), DMF (N,N-dimethylformamide), and DMAC (N,N-dimethylacetamide).

[0030] Preferably, in step (2), the molar ratio of the intermediate 3-2 to the acid is 1:(3-15), and the amount of solvent used is 8-15 mL of solvent per 1 g of intermediate 3-2.

[0031] Preferably, the acid in step (2) is any one or more of hydrochloric acid and trifluoroacetic acid.

[0032] Preferably, the solvent in step (2) is any one or more of ethyl acetate, dichloromethane and dioxane.

[0033] Preferably, in step (3), the molar ratio of compound 1-1 to oxidant and acid is 1:(2-6):1.05, and the mass ratio of compound 1-1 to solvent is 1:4. In this step, when the amount of oxidant is too low, the reaction period is long and the reaction is not complete; when the amount of oxidant is too high, the impurity content increases. When the amount of acid is too low, the reaction is not complete, and when the amount is too high, the by-product content increases.

[0034] Preferably, in step (3), the oxidant is hydrogen peroxide; the acid is one or more of sulfuric acid, hydrochloric acid, formic acid, and acetic acid. Further, the acid is sulfuric acid.

[0035] More preferably, the hydrogen peroxide is 30% by mass, which is easy to obtain and safe to use.

[0036] Further preferably, the sulfuric acid is concentrated sulfuric acid with a mass fraction greater than or equal to 70%. Concentrated sulfuric acid mainly plays the role of improving oxidation efficiency and promoting substrate dissolution.

[0037] Preferably, the solvent in step (3) is deionized water or tap water.

[0038] Further preferably, the reaction temperature in step (3) is 50-70° C. When the reaction temperature is lower than 50° C., the reaction proceeds slowly; if the reaction temperature is higher than 70° C., impurities increase, resulting in a decrease in yield.

[0039] Preferably, in step (4), the molar ratio of the intermediate compound 2-2 to the intermediate compound 3-3, the condensing agent and the base is 1:(1-1.5):(1-1.5):(3-6), and the amount of solvent used is 10-20 mL of solvent per 1 g of the intermediate compound 2-2.

[0040] Preferably, the condensing agent in step (4) is a phosphonium ion or a phosphate condensation reagent; the phosphonium ion or phosphate condensation reagent is selected from any one or more of BOP (benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate), PyBOP (1H-benzotriazol-1-yloxytripyrrolidino hexafluorophosphate), BOP-Cl (bis(2-oxo-3-oxazolidinyl)phosphinoyl chloride), FDP (sodium fructose 1,6-diphosphate), FDPP (pentafluorophenyl diphenyl phosphate), and DEPBT (3-(diethoxy-o-acyloxy)-1,2,3-benzotriazine-4-one).

[0041] Specifically, the condensing agent is benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate, namely Carter condensing agent (English abbreviation BOP). If the amount of the condensing agent is too low, the reaction will not be thorough; if the amount is too high, the condensing agent will be wasted.

[0042] Preferably, the base in step (4) is a common organic base. Common organic bases refer to any one or more of triethylamine, diisopropylethylamine, diethylamine, and DBU (1,8-diazobispiro[5.4.0]undec-7-ene). Excessive organic base is to neutralize the hydrochloride of intermediate 3-3 and promote the condensation reaction. If the amount of organic base is too low, the reaction will be slow and incomplete.

[0043] Preferably, the solvent in step (4) is one or more polar aprotic solvents such as dichloromethane, dichloroethane or N,N-dimethylformamide; if the reaction solvent is dried dichloromethane, the reaction effect is better.

[0044] Preferably, the reaction in step (4) needs to be carried out under a nitrogen atmosphere.

[0045] Preferably, the reaction temperature in step (4) is room temperature, which refers to 20-30°C.

[0046] Further preferably, the specific steps of the condensation reaction in step (4) are as follows: in an ice-water bath, the intermediate compound 2-2 is dissolved in a solvent, and a condensing agent and a base are added in sequence after nitrogen protection, and the temperature is raised to room temperature (20-30°C) and the reaction is carried out for 1 hour; then the temperature is lowered to 0°C, the intermediate compound 3-3 is added, and the temperature is raised to room temperature and the reaction is carried out overnight.

[0047] The present invention determines that the structure of the oxidation product in a hydrogen peroxide system is an intermediate compound 2-2 through one-dimensional hydrogen spectrum.

[0048] Compared with the prior art, the present invention has the following positive effects:

[0049] 1. In step (3) of the present invention, the sulfuric acid / hydrogen peroxide system is used to replace m-chloroperbenzoic acid, thereby reducing the reagent cost; at the same time, the generation of the by-product m-chlorobenzoic acid is avoided, which not only greatly reduces the risk of environmental pollution, but also reduces the cost of subsequent three waste treatment.

[0050] 2. The use of water as solvent in step (3) of the present invention not only effectively reduces the cost, but also avoids the use of the organic solvent dichloromethane, effectively avoids environmental pollution, and reduces the cost of subsequent three waste treatment.

[0051] 3. The post-treatment in step (3) of the present invention only requires the addition of an organic solvent, extraction and recrystallization to obtain the intermediate compound 2-2, thus avoiding column chromatography and saving a lot of time and cost.

[0052] 4. In step (4) of the present invention, the intermediate compound 2-2 is directly condensed with the intermediate compound 3-3 under condensation conditions to obtain the target product SNDX-5613 in one step. This reaction not only avoids the use of phosphorus oxychloride, effectively improves the safety of the reaction, but also reduces the generation of waste gas and waste liquid, saves the cost of treating the three wastes, and avoids pollution to the environment. Importantly, this reaction shortens the synthesis route, saving time and cost.

[0053] 5. The present invention advances the nucleophilic substitution reaction (reaction with fragment S1) in the last step of the prior art route, thereby increasing the reaction yield of the carbon-nitrogen bond construction step from 36.8% to 92.6%.

[0054] 6. The present invention optimizes the five-step linear synthesis route of the prior art route into a four-step convergent synthesis route, and optimizes the synthesis yield from 16.2% of the original route to 37.3%. DETAILED DESCRIPTION

[0055] The present invention is described in detail below by way of examples. It should be noted that the following examples are only for further explanation of the present invention and cannot be understood as limiting the scope of protection of the present invention, and non-essential adjustments and improvements made by those skilled in the art according to the above invention content still belong to the scope of protection of the present invention.

[0056] Example 1

[0057] Step (1) The substitution reaction mainly consists of the following steps:

[0058] 1) Compound S1 (550 g, 1.46 mol) was dissolved in NMP (2.5 L), potassium iodide (159.3 g, 0.96 mol) was added, and the mixture was stirred at room temperature for 15 min after replacing nitrogen;

[0059] 2) Potassium carbonate (911.8 g, 6.60 mol) and compound 3-1 (264.3 g, 1.168 mol) were added to the reaction system in sequence, and the nitrogen was replaced again and the temperature was raised to 75°C for reaction overnight;

[0060] 3) monitoring the completion of the reaction by thin layer chromatography or liquid chromatography-mass spectrometry;

[0061] 4) After the reaction solution is cooled, it is filtered, and the filter cake is washed three times with an appropriate amount of ethyl acetate. The filtrate is diluted with ethyl acetate (15 L), the filtrate is washed three times with water, the filtrate is washed twice with saturated brine, and the organic phase is concentrated after drying with anhydrous sodium sulfate. The obtained crude product is dispersed and slurried with a mixed solvent of petroleum ether / ethyl acetate = 5:1, and the target product 3-2 (465 g, 1.08 mol) is obtained by filtration. HPLC purity: 96%, mass spectrum data: [M+H] + =430, yield: 92.6%.

[0062] Step (2) the deprotection reaction mainly consists of the following steps:

[0063] 1) Dissolve intermediate 3-2 (465 g, 1.08 mol) in ethyl acetate (1.1 L), add 4 M hydrochloric acid ethyl acetate solution (3.0 L, 12.0 mol) dropwise in an ice bath, and stir at room temperature overnight;

[0064] 2) monitoring the completion of the reaction using thin layer chromatography or liquid chromatography-mass spectrometry;

[0065] 3) Filter, wash the filter cake with ethyl acetate three times, collect the filter cake and concentrate to obtain the target intermediate compound 3-3 (470 g). HPLC purity: 96%, mass spectrum data: [M+H] + =330, yield: 100%.

[0066] Step (3) The oxidation reaction mainly consists of the following steps:

[0067] 1) Slowly add concentrated sulfuric acid (230 ml, 98%) to a reaction vessel containing solvent water (5.2 L), cool down (<30°C) and stir while adding. At room temperature, add compound 1-1 (1.3 kg, 4.28 mol) and disperse it in the reaction system. Then slowly add hydrogen peroxide (884 mL, 30%) dropwise. After the dropwise addition, heat to 60°C and stir overnight.

[0068] 2) monitoring the completion of the reaction using thin layer chromatography or liquid chromatography-mass spectrometry;

[0069] 3) After the reaction is completed, a sodium sulfite aqueous solution is added dropwise to the reaction system while cooling, and after quenching the excess hydrogen peroxide, dichloromethane is added to the reaction system for extraction three times, and the organic phases are combined and concentrated to obtain a crude product;

[0070] 4) The obtained crude product was recrystallized with an appropriate amount of ethyl acetate / petroleum ether and filtered to obtain the target intermediate compound 2-2 (723.6 g, 2.27 mol). HPLC purity: 95%, NMR data: 1 H NMR (400 MHz, DMSO-d6) δ 12.94 (s, 1H), 8.10 (d, J = 1.8 Hz, 1H), 7.77 (d, J = 3.0 Hz, 1H), 7.21–7.12 (m, 2H), 6.97–6.89 (m, 1H), 3.87 (p, J = 6.6 Hz, 1H), 3.37 (dt, J = 13.5, 6.7 Hz, 1H), 3.24 (dt, J = 13.6, 6.9 Hz, 1H), 1.18 (d, J = 7.1 Hz, 2H), 1.14–1.07 (m, 5H), 1.05 (d, J = 6.6 Hz, 2H). Mass spectral data: [M+H] + =320, yield: 53%.

[0071] The NMR data of intermediate 2-2 after heavy water exchange were: 1 H NMR (400MHz, DMSO-d6) δ8.05(d,J=1.8Hz,1H),7.71(d,J=3.0Hz,1H),7.18–7.09(m,2H),6.93–6.85(m,1H),3.82(p,J=6.6Hz,1 H),3.34(dt,J=13.5,6.7Hz,1H),3.19(dt,J=13.6,6.9Hz,1H),1.15(d,J=7.1Hz,2H),1.10–1.04(m,5H),1.01(d,J=6.6Hz,2H).

[0072] Step (4) condensation reaction mainly consists of the following steps:

[0073] 1) Under an ice-water bath, the intermediate compound 2-2 (220 g, 0.689 mol) was dissolved in dichloromethane (3.3 L), and under nitrogen protection, the condensation agent BOP (336 g, 0.76 mol) and triethylamine (384 g, 3.79 mol) were added in sequence, and the temperature was raised to room temperature (20-30°C) and reacted for 1 h; then the temperature was lowered to 0°C, and the intermediate compound 3-3 (272 g, 0.83 mol) was added, and the temperature was restored to room temperature and reacted overnight.

[0074] 2) Monitor the completion of the reaction using thin layer chromatography or liquid chromatography-mass spectrometry.

[0075] 3) After the reaction is completed, dichloromethane is added to dilute and quench. After extraction and separation, the organic phase is washed with water twice, washed with saturated ammonium chloride aqueous solution 6 times, washed with saturated brine 1-2 times, and the organic phase is concentrated to obtain a crude product.

[0076] 4) Disperse the crude product in an appropriate volume of ethyl acetate, heat until completely dissolved, and add petroleum ether dropwise at this temperature until the solution becomes turbid. Cool naturally and stir to precipitate solids, which are filtered to obtain the target product SNDX-5613 (330 g, 0.523 mol). HPLC purity: 98.8% (measured by HPLC), NMR data: 1 H NMR(600MHz,Chloroform-d)δ8.39–8.34(m,1H),7.76(d,J=1.7Hz,1H),7.01(qd,J=7.4,7.0,3.5Hz,2H),6.77(ddd,J=14.2,9. 5,4.1Hz,1H),4.62(p,J=6.9Hz,0.2H),4.02–3.77(m,5H),3.50(dd,J=13.7,7.0Hz,0.8H),3.31(dd,J=13.7,7.0Hz,1H),3.19(d d, J = 9.0, 5.6 Hz, 1H), 3.07–2.98 (m, 2H), 2.26 (s, 4H), 2.06 (dd, J = 11.8, 5.0 Hz, 4H), 1.78 (dd, J = 53.4, 9.5 Hz, 7H), 1.36 (ddd, J = 7.4, 5.8, 1.7 Hz, 3H), 1.27–1.19 (m, 5H), 1.14 (t, J = 6.6 Hz, 5H), 1.08 (dd, J = 7.9, 6.4 Hz, 1H), 0.94 (q, J = 12.9 Hz, 2H). Mass spectral data: [M+H] + =631, yield: 76%.

Claims

1. An intermediate compound for synthesizing the menin inhibitor SNDX-5613, which has a structure shown in Formula 2-2 and / or Formula 3-3:

2. The method for synthesizing the intermediate compound 2-2 according to claim 1, comprising step (3): (3) Dissolve compound 1-1 in a solvent, add an oxidant to oxidize under the action of an acid, and react at 50-70° C. for 16-24 hours to obtain an intermediate compound 2-2; The reaction route is as follows:

3. The method for synthesizing the intermediate compound 3-3 according to claim 1, comprising step (1) and step (2): (1) Dissolve compound S1 and a catalyst in a solvent, stir for 10 to 30 minutes, then add a base and compound 3-1, heat to 70 to 80°C under nitrogen protection, and react for 12 to 24 hours to obtain intermediate 3-2; (2) Dissolving the intermediate 3-2 in a solvent, adding an acid to remove the protecting group, and obtaining the intermediate compound 3-3; The reaction route is as follows:

4. A method for synthesizing a menin inhibitor SNDX-5613, comprising the following steps: (1) Dissolve compound S1 and a catalyst in a solvent, stir for 10 to 30 minutes, then add a base and compound 3-1, heat to 70 to 80°C under nitrogen protection, and react for 12 to 24 hours to obtain intermediate 3-2; (2) Dissolving the intermediate 3-2 in a solvent, adding an acid to remove the protecting group, and obtaining the intermediate compound 3-3; (3) Dissolve compound 1-1 in a solvent, add an oxidant to oxidize under the action of an acid, and react at 50-70° C. for 16-24 hours to obtain an intermediate compound 2-2; (4) The intermediate compound 2-2 is dissolved in a solvent, and reacted with the intermediate compound 3-3 at 0-30° C. for 12-24 h in the presence of a condensing agent and a base to obtain SNDX-5613.

5. The method according to claim 3 or 4, characterized in that: The molar ratio of compound S1 to the catalyst, compound 3-1 and base in step (1) is 1:(0.8-1):(0.5-1):(3-5), and the amount of solvent used is 4-15 mL of solvent per 1 g of compound S1.

6. The method according to claim 5, characterized in that: The catalyst in step (1) is any one or more of potassium iodide and sodium iodide; the base in step (1) is any one or more of potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, and lithium hydroxide; the solvent in step (1) is any one or more of N-methylpyrrolidone, dimethyl sulfoxide, N,N-dimethylformamide, and N,N-dimethylacetamide.

7. The method according to claim 3 or 4, characterized in that: The molar ratio of the intermediate 3-2 to the acid in step (2) is 1:(3-15), and the amount of solvent used is 8-15 mL of solvent per 1 g of intermediate 3-2.

8. The method according to claim 7, characterized in that: The acid in step (2) is any one or more of hydrochloric acid and trifluoroacetic acid; the solvent in step (2) is any one or more of ethyl acetate, dichloromethane and dioxane.

9. The method according to claim 2 or 4, characterized in that: The molar ratio of compound 1-1 to the oxidant and the acid in step (3) is 1:(2-6): 1.05, and the mass ratio of compound 1-1 to the solvent is 1:

4.

10. The method according to claim 9, characterized in that: The solvent in step (3) is water; the oxidant in step (3) is hydrogen peroxide; the acid in step (3) is one or more of sulfuric acid, hydrochloric acid, formic acid, and acetic acid.

11. The method according to claim 4, characterized in that: In step (4), the molar ratio of the intermediate compound 2-2 to the intermediate compound 3-3, the condensing agent and the base is 1:(1-1.5):(1-1.5):(3-6), and the amount of solvent used is 10-20 mL of solvent per 1 g of the intermediate compound 2-2.

12. The method according to claim 11, characterized in that: The solvent in step (4) is selected from any one or more of dichloromethane, dichloroethane or N,N-dimethylformamide; the condensing agent in step (4) is a phosphonium ion or a phosphate condensation reagent; the base in step (4) is selected from any one or more of triethylamine, diisopropylethylamine, diethylamine, and 1,8-diazobispiro[5.4.0]undec-7-ene.

13. The method according to claim 12, characterized in that: The phosphonium cation or phosphate condensation reagent is selected from any one or more of benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate, 1H-benzotriazol-1-yloxytripyrrolidino hexafluorophosphate, bis(2-oxo-3-oxazolidinyl)phosphinoyl chloride, sodium fructose-1,6-diphosphate, pentafluorophenyl diphenyl phosphate, and 3-(diethoxy-o-acyloxy)-1,2,3-benzotriazine-4-one.

Citation Information

Patent Citations

  • Inhibitors of the menin-MLL interaction

    CN109743875A

  • Methods for treating hematological malignancies and ewing's sarcoma

    CN110691779A

  • Treatment of hematological malignancies with inhibitors of menin

    CN113164443A

  • Treatment of hematological malignancies with inhibitors of menin

    WO2022086986A1